Redcare Pharmacy stock weighs confirmed 2026 targets against margin test
Published on 11/12/2026 at 11:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth now faces a margin test
- Redcare Pharmacy confirmed its 2026 revenue growth target of 16% to 18%.
- Third-quarter adjusted EBITDA rose 68%, while the adjusted EBITDA margin reached 3.4%.
- Competition and weaker short-term non-prescription demand remain key execution risks.
Redcare Pharmacy's confirmed 2026 targets leave investors focused on whether stronger sales can translate into durable profitability. In an analysis published on Thursday, November 12, Boerse-Express highlighted the tension between improved operating figures, competition and softer short-term expectations.
Redcare Pharmacy reported third-quarter 2026 revenue of EUR 847 million, an increase of 18% from the prior year, according to the company figures cited in the analysis. Adjusted EBITDA rose 68% to EUR 28.7 million, while the adjusted EBITDA margin reached 3.4%, up from 2.4% a year earlier.
Confirmed targets set the hurdle
For the full year, Redcare continues to target revenue growth of 16% to 18% and an adjusted EBITDA margin of 2.5% to 3.0%. The combination matters for the investment case: revenue growth can expand the business, but only a sustained margin can turn that expansion into stronger earnings quality.
The analysis also points to pressure in non-prescription products at the start of October and to a competitive market. That makes the confirmed guidance a test of execution rather than a guarantee of an unchanged trajectory. Investors will need to watch whether demand improves without forcing Redcare to spend more heavily to defend market share.
Redcare Pharmacy stock traded at EUR 71.20 on Lang & Schwarz at 11:09 CET on Thursday, November 12, 2026, 0.14% above the Xetra close of Wednesday, November 11, 2026.
Profitability remains the key signal
The latest figures provide a stronger operating base than the prior year, but the outlook still depends on maintaining growth while protecting margins. For shareholders, the central question is whether prescription momentum and scale can offset competition and weaker non-prescription demand.
Redcare Pharmacy stock at a glance
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Ticker: RDC
- Lang & Schwarz price: EUR 71.20 at 11:09 CET on November 12, 2026
- Change versus Xetra close: 0.14% above EUR 71.10 on November 11, 2026
- 2026 revenue target: 16% to 18% growth
- 2026 adjusted EBITDA margin target: 2.5% to 3.0%
European equity markets remain an important backdrop for valuation and risk appetite; see Current market reports.
Further company-specific developments are collected under More news and analyses on Redcare Pharmacy stock.
